ClinicalTrials.gg
RecruitingNCT07553754EXO-METUpdated Apr 28, 2026

Plasma Exosomal RNA Signature for Prostate Cancer Bone Metastasis

An observational study in Prostate Cancer (Diagnosis), Bone Metastasis and PSMA PET, sponsored by Xijing Hospital. Recruiting at 9 sites in China. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-28.

Sponsored by Xijing Hospital · Observational

How we know

From the registry’s dates

  • Started Mar 2026; still recruiting 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
1,000
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies in Prostatic Neoplasms by Xijing Hospital — 10 open to participants now, 10 under way, none of them phase 3. Prostatic Neoplasms · Xijing Hospital.

Started
2026
with 1 other
Observational
6 of 10
6 open now
Registered
6th of 10
by date

Among the 10 studies in Prostatic Neoplasms by Xijing Hospital, this one is one of 2 that started in 2026, is one of 6 observational ones, and was the 6th registered.

Prostatic Neoplasms

7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

10 of the 10 studies in Prostatic Neoplasms by Xijing Hospital are open now, in 2 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 10 open studies →

Where they have run

Who these studies take

Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Prostatic Neoplasms by Xijing Hospital, or all of them as a file.
02

Study summary

Brief Summary:

This prospective, multicenter study aims to discover, develop, and validate a plasma exosomal RNA-based signature as a rule-out test for predicting bone metastasis in prostate cancer, using baseline treatment-naïve PSMA PET as the gold standard. The study is designed in four sequential phases:

Phase 1 (Discovery, n=250): High-throughput sequencing of plasma exosomal RNAs to identify differentially expressed candidate RNAs.

Phase 2 (Model Development, n=300): Digital droplet PCR (ddPCR) analysis of candidates in an independent cohort to construct and lock the final multi-RNA predictive signature using appropriate machine learning methods.

Phase 3 (Internal Validation, n=300): Independent validation of the locked signature in a consecutive cohort reflecting natural disease prevalence.

Phase 4 (External Validation, n=150): Final independent validation in a multi-center cohort enriched for bone metastasis.

Primary Outcome:

To evaluate the diagnostic performance of the signature as a rule-out test for PSMA PET-defined bone metastasis. The primary performance metrics are:

Sensitivity, with a prespecified target of ≥95% (to ensure minimal false negatives).

Specificity at the threshold that achieves the ≥95% sensitivity. A specificity of ≥30% will be considered supportive of clinical utility. A specificity of ≥30% (or a lower bound of the 95% confidence interval exceeding 20%) will be considered supportive of clinical utility.

Need:

Current biomarkers lack sensitivity and specificity for early detection of bone metastasis. More importantly, existing tools lack adequate negative predictive value to safely rule out bone metastasis in low-risk patients, leading to over-imaging or delayed detection. There is an urgent need for a non-invasive rule-out test to safely defer PSMA PET/CT in very-low-risk patients. Plasma exosomal RNAs offer a promising liquid biopsy approach, but prospective multicenter studies with rigorous validation are lacking.

Secondary Outcomes:

  1. Secondary metrics include negative predictive value (NPV), positive predictive value (PPV), area under the ROC curve (AUC), calibration, and decision curve analysis.
  2. Correlation between exosomal RNA levels and number of bone metastatic lesions (PSMA PET).
  3. Association with PSA, PSMA PET SUVmax, and MRI findings.
  4. Tissue-plasma correlation to confirm tumor origin (exploratory).
  5. Mechanistic exploration of key candidates via in vitro/in vivo assays (exploratory).
  6. Subgroup analyses by hormone sensitivity, metastatic pattern, Gleason grade (exploratory).

Inclusion Criteria:

  1. Histologically confirmed prostate cancer scheduled for baseline PSMA PET.
  2. PSMA PET performed prior to any prostate cancer-related treatment.
  3. Blood samples collected prior to any treatment AND prior to prostate biopsy.
  4. Willing to undergo prostate biopsy if clinically indicated (after blood collection).
  5. Written informed consent.
  6. Age ≥18 years.

Exclusion Criteria:

  1. Any prior prostate cancer treatment before baseline PSMA PET.
  2. Blood samples collected after prostate biopsy.
  3. Other active malignancy within past two years (excluding non-melanoma skin cancer).
  4. Inadequate blood sample quality or quantity.
  5. Severe comorbidities interfering with study conduct.
Read the detailed description

Background Prostate cancer (PCa) is a leading cause of cancer-related morbidity worldwide, with bone metastasis being the most frequent and devastating complication. Early and accurate detection of bone metastasis is critical for timely intervention and improved patient outcomes. However, current biomarkers such as PSA lack sufficient sensitivity and specificity for early metastasis detection, and conventional imaging (e.g., bone scan, CT) often identifies metastases only after they become clinically apparent. PSMA PET has emerged as the most sensitive imaging modality for defining metastatic status at baseline, but its high cost, limited availability, and radiation exposure preclude its use as a universal screening tool.

Concurrently, liquid biopsy-particularly the analysis of plasma exosomal RNAs-offers a unique window into tumor biology. Exosomal RNAs are stable in circulation, reflect the molecular characteristics of the primary tumor, and can be detected using sensitive methods such as high-throughput sequencing and digital droplet PCR. Despite their promise, large-scale prospective multicenter studies with rigorous multi-phase validation are lacking.

Need There is a critical unmet need for a non-invasive, robust biomarker that can identify patients at very low risk of bone metastasis, thereby allowing safe deferral of PSMA PET/CT. Existing tools lack adequate negative predictive value to confidently rule out bone metastasis in low-risk populations. A successful rule-out test would reduce unnecessary imaging, lower healthcare costs, and minimize patient radiation exposure. This study implements a four-stage design with phase-specific sample size considerations aligned with contemporary standards for biomarker development.

Study Design and Technical Phases This is a prospective, multicenter, phase-sequential biomarker development and validation study. The gold standard for bone metastasis status is baseline, treatment-naïve PSMA PET/CT. All blood samples are collected prior to any prostate cancer-related treatment and prior to prostate biopsy (if performed) to avoid biopsy-induced contamination. Whole blood (approximately 10 mL in EDTA tubes) is processed within 2 hours to obtain plasma, which is stored at -80°C until analysis.

The four phases are defined as:

Phase 1 (Discovery, n=250): High-throughput RNA sequencing (e.g., small RNA-seq) of plasma exosomes. Differential expression analysis (e.g., DESeq2 or edgeR) identifies candidate RNAs distinguishing patients with versus without bone metastasis. Multiple testing correction (FDR \<0.05) is applied.

Phase 2 (Model Development, n=300): An independent cohort enriched for bone metastasis (approximately 200 positive, 100 negative) is used for quantitative measurement of candidate RNAs using ddPCR. A continuous risk-scoring model is constructed using machine learning (e.g., regularized regression, random forests, or gradient boosting). The model is locked after internal cross-validation, before any validation data are examined.

Phase 3 (Internal Validation, n=300): A consecutive cohort reflecting natural disease prevalence (expected bone metastasis rate \~30%) is used to evaluate the locked model. In this phase, a single cut-off value is selected to achieve a sensitivity of ≥95%. The specificity at that cut-off is the primary endpoint. Secondary metrics (NPV, PPV, AUC, calibration, decision curve analysis) are also assessed.

Phase 4 (External Validation, n=150): A geographically distinct, multi-center cohort enriched for bone metastasis is used to assess generalizability, applying the same cut-off determined in Phase 3.

Statistical Considerations Sample Size Justification Sample sizes were chosen based on published recommendations for phased biomarker studies and on formal precision analysis for the primary endpoint (specificity at the ≥95% sensitivity threshold).

Phase 1 (Discovery, n=250): This sample size is typical for high-throughput discovery studies. With an expected bone metastasis prevalence of \~30%, approximately 75 positive and 175 negative cases will be available, providing sufficient power to detect differential expression with FDR \<0.05.

Phase 2 (Model Development, n=300): Following the "events per variable" (EPV) rule (≥10 events per candidate predictor) and assuming a parsimonious final model (≤20 candidate RNAs after Phase 1), a minimum of 200 positive events is required. The cohort is enriched for bone metastasis (target \~67% positive), thus a total of 300 patients (≈200 positive, ≈100 negative) is planned.

Phase 3 (Internal Validation, n=300): The primary endpoint is specificity at the cut-off achieving ≥95% sensitivity. Assuming a true specificity of 35% at this threshold, a sample of approximately 210 negative patients (from total n=300 with \~30% bone metastasis prevalence) yields a 95% confidence interval half-width of approximately ±6-7%. This precision is more than sufficient to rule out a clinically useless specificity (e.g., \<15%) and allows robust subgroup analyses.

Phase 4 (External Validation, n=150): This multi-center cohort is enriched for bone metastasis (target \~40-50% positive). The sample size of 150 (≈75 positive, ≈75 negative) allows precise estimation of specificity (95% CI half-width ±11% assuming 35% specificity) and sensitivity in an independent setting, confirming generalizability.

All sample sizes may be adjusted modestly based on actual recruitment; any adjustments will be documented.

Statistical Analysis Plan (High-Level) Analyses will be performed using R (version ≥4.2). The final analysis plan will be finalized before locking validation data.

Phase 1: Differential expression analysis (DESeq2/edgeR). Candidate selection based on fold change, adjusted p-value, and abundance.

Phase 2: Machine learning model building using cross-validation. The final continuous model is locked.

Phase 3: Apply the locked model to the internal validation cohort. Determine the cut-off value that achieves sensitivity ≥95%. Report specificity, NPV, PPV, AUC, calibration, and decision curve analysis at this cut-off.

Phase 4: Apply the same cut-off to the external validation cohort and repeat the performance evaluation.

Secondary/exploratory analyses: Correlation, subgroup analyses, mechanistic studies (as detailed in the secondary outcome measures).

Data Management Data will be stored centrally in a REDCap database with 3-step authentication. Data entry will occur approximately every 3-6 months. Patient confidentiality will be maintained.

03

Conditions studied

  • Prostate Cancer (Diagnosis)
  • Bone Metastasis
  • PSMA PET
  • Liquid Biopsy
  • Exosomal RNA
  • Biomarker Discovery and Validation
  • Treament-naive

Keywords

  • Prostate Cancer
  • Bone Metastasis
  • PSMA PET
  • Liquid Biopsy
  • Exosomal RNA
  • Predictive Signature
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study enrolls a total of approximately 1000 patients with histologically confirmed prostate cancer from multiple centers. All patients undergo baseline PSMA PET/CT and provide pre-treatment blood samples (collected before any therapy and before prostate biopsy). The single overall cohort is allocated into four sequential, independent phases: Phase 1 (Discovery, n=250), Phase 2 (Model Development, n≥300, bone-metastasis enriched), Phase 3 (Internal Validation, n≥300, natural prevalence), and Phase 4 (External Validation, n=150, multi-center enriched). Bone metastasis status is defined by PSMA PET/CT.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients with confirmed prostate cancer who are scheduled to undergo baseline PSMA PET imaging.
  2. Patients who undergo PSMA PET imaging prior to any prostate cancer-related treatment (including androgen deprivation therapy, radiotherapy, or surgery).
  3. Patients who provide blood samples for plasma exosomal RNA analysis collected prior to any treatment AND prior to prostate (if applicable).

    Whole blood samples (approximately 10 mL) will be collected in EDTA tubes at this specified time point. Samples will be processed within 2 hours to obtain plasma and stored at -80°C until analysis.This timing ensures circulating exosomal RNA profiles reflect tumor biology without biopsy-induced contamination.

  4. Patients who are willing to undergo prostate biopsy if clinically indicated (biopsy performed after blood collection).
  5. Patients who provide written to participate in the study.
  6. Age ≥18 years.

Exclusion criteria

Exclusion Criteria

  1. Patients who have received any prior prostate cancer-related treatment before the baseline PSMA PET scan (including hormonal therapy, radiotherapy, chemotherapy, or surgery).
  2. Patients whose blood samples were collected after prostate .
  3. Patients with a history of other active within the past two years (excluding non-melanoma skin cancer).
  4. Patients with inadequate blood sample quality or quantity for exosomal RNA extraction and analysis (e.g., hemolysis, insufficient volume \<8 mL).
  5. Patients with severe comorbidities or conditions that, in the judgment of the investigator, could interfere with study compliance or pose significant risk.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
1,000 participants (estimated)
Patient registry
No

Groups and cohorts

  • Prostate Cancer Cohort

    A single cohort of 1000 patients with suspected or histologically confirmed prostate cancer who undergo baseline treatment-naïve PSMA PET imaging. All patients provide blood samples for plasma exosomal RNA analysis, collected prior to any treatment and prior to prostate biopsy. This cohort is used for a four-phase biomarker study: Phase 1 (Discovery, n=250) for RNA sequencing to identify candidate biomarkers; Phase 2 (Model Development, n=300) for digital PCR-based signature development; Phase 3 (Internal Validation, n=300) for independent validation in a consecutive cohort; and Phase 4 (External Validation, n=150) for multi-center validation. Bone metastasis status is defined by PSMA PET. Phase 2 and Phase 3 cohorts are temporally and geographically independent. No patient is included in more than one phase

06

What researchers measure

Primary outcomes

  1. Specificity of the plasma exosomal RNA-based predictive signature for detecting PSMA PET-defined bone metastasis at a prespecified sensitivity threshold of ≥95%

    Description: The signature will be developed as a continuous risk score using machine learning in an independent development cohort (Phase 2, n≥300, enriched for bone metastasis). After locking the model, a single cut-off value will be selected in the internal validation cohort (Phase 3, n≥300, reflecting natural disease prevalence) to achieve a sensitivity of ≥95% for detecting PSMA PET/CT-defined bone metastasis. The primary outcome is the specificity of the signature at that cut-off. A specificity of ≥30% (or a lower bound of the 95% confidence interval exceeding 20%) will be considered supportive of clinical utility. Measurement tools and units: Plasma exosomal RNA level: digital droplet PCR (ddPCR), expressed as absolute copy number per mL of plasma. Bone metastasis status: PSMA PET/CT, binary (positive/negative). Sensitivity and specificity: proportions with 95% confidence intervals (Clopper-Pearson exact method).

    Time frame: Baseline

Secondary outcomes

  1. Correlation between plasma exosomal RNA level and bone metastatic lesion count on PSMA PET

    The number of bone metastatic lesions will be quantified by PSMA PET/CT as a discrete count. The Spearman rank correlation coefficient (rho) will be calculated to assess the monotonic association with exosomal RNA level.

    Time frame: Baseline

  2. Correlation between plasma exosomal RNA level and serum PSA level

    Serum PSA will be measured in ng/mL using standard clinical laboratory methods. Spearman correlation coefficient will be calculated.

    Time frame: Baseline

  3. Correlation between plasma exosomal RNA level and PSMA PET SUVmax

    SUVmax (maximum standardized uptake value) will be derived from PSMA PET/CT. Spearman correlation coefficient will be calculated.

    Time frame: Baseline

  4. Association between exo-RNA and MRI findings (exploratory)

    MRI findings will be categorized asPI-RADs scores, "suspicious for bone metastasis" or "not suspicious".

    Time frame: Baseline

  5. Correlation between tissue RNA expression (RNA-seq, normalized counts like FPKM/TPM) and plasma exosomal RNA level (ddPCR, copies/mL)

    In patients with available formalin-fixed paraffin-embedded (FFPE) or fresh frozen tumor tissue samples, RNA expression of the selected exosomal RNA candidates (e.g., the top 2-3 most differentially expressed RNAs from the locked signature) will be measured by RNA sequencing (RNA-seq). Expression levels will be quantified as normalized counts (e.g., fragments per kilobase of transcript per million mapped reads \[FPKM\] or transcripts per million \[TPM\]) using standard bioinformatics pipelines (e.g., STAR + featureCounts + DESeq2 normalization). The corresponding plasma exosomal RNA level of the same candidate is measured by digital droplet PCR (ddPCR) and expressed as absolute copy number per mL of plasma. The Spearman rank correlation coefficient (rho) and its 95% confidence interval will be calculated to assess the strength of association between tissue and plasma levels.

    Time frame: Baseline

  6. Mechanistic exploration of key driver candidates via functional assays (exploratory)

    For the most significantly dysregulated RNA candidate(s) from the validated signature, functional assays will be performed: Cell proliferation: CCK-8 assay measured as absorbance at 450 nm, or EdU assay measured as percentage of EdU-positive cells. Cell migration/invasion: Transwell assay measured as number of migrated/invaded cells per high-power field (average of 5 fields). In vivo tumor growth: tumor volume measured by caliper in mm³ using formula (length × width²)/2. In vivo metastasis: number of macroscopic metastatic nodules counted. Descriptive statistics (mean ± SD, median with IQR) will be reported.

    Time frame: Baseline

  7. Subgroup analyses of diagnostic performance (exploratory)

    The locked signature's performance (sensitivity, specificity, negative predictive value, positive predictive value) will be calculated separately for: Hormone-sensitive vs. castration-resistant prostate cancer Oligometastatic (≤3 lesions) vs. polymetastatic (\>3 lesions) disease Gleason grade group ≤7 vs. ≥8 Each performance metric will be reported with 95% confidence intervals.

    Time frame: Baseline

07

Study locations

9 of 9 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Jun 2027, 15 months after the start.

Of 542 non-industry observational studies under Prostatic Neoplasms, half reached primary completion within 67 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 162. This study's planned 15 months is below that.

Counting every sponsor, half of 651 studies reached it within 60 months; a quarter within 28 and three quarters within 141.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 11, 2026
First posted
Apr 28, 2026
StartActual
Mar 12, 2026
Primary completionEst.
Jun 30, 2027
CompletionEst.
Dec 31, 2027
Last update
Apr 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 28, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07553754
Lead sponsor
Xijing Hospital
Collaborators
Air Force Military Medical University, China, Shaanxi Provincial People's Hospital, Yan'an University Affiliated Hospital, Weinan Central Hospital, The Second Affiliated Hospital of Shaanxi University of Chinese Medicine, LanZhou University, Qinghai University, General Hospital of Ningxia Medical University
Responsible party
Sponsor
First posted
Apr 28, 2026
Start date
Mar 12, 2026
Primary completion
Jun 30, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Apr 28, 2026

Study contacts

Jianhua Jiao, MD.
Contact
1531769428@qq.com
+86 18700919857

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion